Register Login

OCUGEN, INC. (OCGN)

SymbolOCGN
NameOCUGEN, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
Address11 GREAT VALLEY PARKWAY, MALVERN, Pennsylvania, 19355, United States
Telephone+1 484 - 328-4701
Fax—
Email—
Websitehttps://www.ocugen.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001372299
Description

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotechs COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Additional info from NASDAQ:
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotechs COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.

2026-08-13 13:42

New Form SCHEDULE 13G/A - Ocugen, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001274173-26-000196 <b>Size:</b> 12 KB

Read more
2026-08-07 11:29

New Form SCHEDULE 13G - Ocugen, Inc. <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000513 <b>Size:</b> 8 KB

Read more
2026-08-06 11:02

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Read more
2026-07-31 11:02

Ocugen to Participate in Upcoming August Investor Conferences

Read more
2026-07-30 17:37

New Form DEFA14A - Ocugen, Inc. <b>Filed:</b> 2026-07-30 <b>AccNo:</b> 0001140361-26-030261 <b>Size:</b> 3 MB

Read more
2026-07-30 17:31

New Form DEF 14A - Ocugen, Inc. <b>Filed:</b> 2026-07-30 <b>AccNo:</b> 0001140361-26-030258 <b>Size:</b> 8 MB

Read more
2026-07-29 11:01

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Read more
2026-07-20 18:01

New Form PRE 14A - Ocugen, Inc. <b>Filed:</b> 2026-07-20 <b>AccNo:</b> 0001140361-26-028979 <b>Size:</b> 6 MB

Read more
2026-07-01 11:00

Ocugen to Participate in Upcoming July Industry Conferences

Read more
2026-06-17 20:13

Johnson-Greene Treerita Essalima 🟢 acquired 21.0K shares of Ocugen, Inc. (OCGN) at $1.23 Transaction Date: Jun 15, 2026 | Filing ID: 043886

Read more